Progressive Multiple Sclerosis study of MIS416 advances
Posted: Tue Nov 15, 2011 1:33 am
Innate Immunotherapeutics today announced that the dose confirmation part of the company's Phase 2A trial of drug candidate MIS416 in patients with the progressive form of MS will commence in early January 2012.
The announcement follows the successful conclusion of a of a dose escalation study in 16 patients with either primary progressive or secondary progressive MS conducted at Primorus Clinical Trials (Christchurch, NZ). The upcoming dose confirmation study will test a potentially therapeutic dose level of MIS416 in 15 patients with secondary progressive MS over a three month period.
Both parts of the 2A study are designed to establish the safety and tolerability of Innate Immunotherapeutics' immune modulating microparticle and to also establish a dose level to be trialed in a larger scale Phase 2B clinical trial in late 2012.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397